Eli Lilly and Company

Andrew Michael Ratz

William George Trankle

Michael Robert Wiley

Gerald Floyd Smith

John Joseph Masters

David Kent Herron

Ying Kwong Yee

David Mendel

Angela Lynn Marquart

Daniel Jon Sall

Jolie Anne Bastian

Vincent Patrick Rocco

Cynthia Darshini Jesudason

Theo Schotten

Jeffry Bernard Franciskovich

Leander Merritt

Patrick Gianpietro Spinazze

John Arnold Werner

Don Richard Finley

Freddie Craig Stevens

John Xiaoqiang He

Gerd Reuhter

Henry U Bryant

Jeffrey A Dodge

Alan David Palkowitz

Brian Stephen Muehl

Theodore Goodson, Jr

Timothy Alan Shepherd

Kenneth Jeff Thrasher

Charles Willis Lugar, Iii

Roger L Robey

James Densmore Copp

Mark Louis Heiman

Charles A Alt

Kenneth Lee Hauser

Gary A Rhodes

William Harlan Gritton

Scott Alan Jones

Paul Leslie Ornstein

Valentine Joseph Klimkowski

Louis Nickolaus Jungheim

Thomas M Wilson

Sajan Joseph

Kennan Joseph Fahey

Leland O Weigel

Anne Louise Tebbe

Jeffrey Daniel Cohen

Ana Maria Escribano

Thomas John Bleisch

Ana Isabel Mateo Herranz

Rushad Eruch Karanjawala

Britta Evers

David E Seyler

Jared Harris Linebarger

Salvatore Donato Lepore

Jose Antonio Martinez-Perez

Joseph Henry Kennedy

Scott Allan May

Ankush Baburao Argade

Theodore Junior Goodson

Ankush B Rigel Pharmaceuticals Inc Argade

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a). 

Aromatic ether derivatives useful as thrombin inhibitors

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. 

Antithrombotic diamides

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I). 

Antithrombotic ethers

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Antithrombotic aromatic ethers

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity 

&#x3b2;3 adrenergic agonists

The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).

Excitatory amino acid receptor antagonists

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;3 agonists

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

Growth hormone secretagogues

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;-3 agonists

The present invention relates to processes for resolving N-methyl-3(R,S)-hydroxy-3-phenylpropylamine and N,N-dimethyl-3 (R,S) -hydroxy-3-phenylpropylamine with the isomers of mandelic acid and the resulting salts.

Process to make chiral compounds

Growing community of inventors

Zionsville, IN, United States of America

Andrew Michael Ratz